JP5820874B2 - Ｎ−（４−（２−アミノ−３−クロロピリジン−４−イルオキシ）−３−フルオロフェニル）−４−エトキシ−１−（４−フルオロフェニル）−２−オキソ−１，２−ジヒドロピリジン−３−カルボキサミドを含有する医薬組成物 - Google Patents

Ｎ−（４−（２−アミノ−３−クロロピリジン−４−イルオキシ）−３−フルオロフェニル）−４−エトキシ−１−（４−フルオロフェニル）−２−オキソ−１，２−ジヒドロピリジン−３−カルボキサミドを含有する医薬組成物 Download PDF

Info

Publication number
JP5820874B2
JP5820874B2 JP2013508267A JP2013508267A JP5820874B2 JP 5820874 B2 JP5820874 B2 JP 5820874B2 JP 2013508267 A JP2013508267 A JP 2013508267A JP 2013508267 A JP2013508267 A JP 2013508267A JP 5820874 B2 JP5820874 B2 JP 5820874B2
Authority
JP
Japan
Prior art keywords
compound
cancer
weight
particles
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013508267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013525455A5 (enExample
JP2013525455A (ja
Inventor
ディルバー・エス・ビンドラ
マドゥシュリー・イェシュワント・ゴカレ
クレトゥス・ジョン・ヌネス
ビクター・ダブリュー・ロッソ
グレッチェン・エム・シュローダー
アジット・ビー・タクール
シアオティアン・イン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2013525455A publication Critical patent/JP2013525455A/ja
Publication of JP2013525455A5 publication Critical patent/JP2013525455A5/ja
Application granted granted Critical
Publication of JP5820874B2 publication Critical patent/JP5820874B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013508267A 2010-04-30 2011-04-29 Ｎ−（４−（２−アミノ−３−クロロピリジン−４−イルオキシ）−３−フルオロフェニル）−４−エトキシ−１−（４−フルオロフェニル）−２−オキソ−１，２−ジヒドロピリジン−３−カルボキサミドを含有する医薬組成物 Active JP5820874B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32971010P 2010-04-30 2010-04-30
US61/329,710 2010-04-30
PCT/US2011/034417 WO2011137274A1 (en) 2010-04-30 2011-04-29 Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-l-(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3 -carboxamide

Publications (3)

Publication Number Publication Date
JP2013525455A JP2013525455A (ja) 2013-06-20
JP2013525455A5 JP2013525455A5 (enExample) 2014-06-05
JP5820874B2 true JP5820874B2 (ja) 2015-11-24

Family

ID=44209564

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013508267A Active JP5820874B2 (ja) 2010-04-30 2011-04-29 Ｎ−（４−（２−アミノ−３−クロロピリジン−４−イルオキシ）−３−フルオロフェニル）−４−エトキシ−１−（４−フルオロフェニル）−２−オキソ−１，２−ジヒドロピリジン−３−カルボキサミドを含有する医薬組成物

Country Status (17)

Country Link
US (2) US8911785B2 (enExample)
EP (1) EP2563763B1 (enExample)
JP (1) JP5820874B2 (enExample)
KR (1) KR101897302B1 (enExample)
CN (1) CN102971296B (enExample)
DK (1) DK2563763T3 (enExample)
ES (1) ES2533075T3 (enExample)
HR (1) HRP20150105T1 (enExample)
MY (1) MY183769A (enExample)
PH (1) PH12012502019A1 (enExample)
PL (1) PL2563763T3 (enExample)
PT (1) PT2563763E (enExample)
RS (1) RS53790B1 (enExample)
SG (1) SG184891A1 (enExample)
SI (1) SI2563763T1 (enExample)
SM (1) SMT201500069B (enExample)
WO (1) WO2011137274A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106635949B (zh) 2011-12-22 2020-05-19 生命技术公司 细胞培养基和方法
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
EP3911320A4 (en) * 2019-01-15 2022-11-30 The Translational Genomics Research Institute PHOSPHONATE CONJUGATES AND THEIR USES
US20230257364A1 (en) * 2022-02-16 2023-08-17 Cmg Pharmaceutical Co., Ltd. Pyridazinone-based compounds as axl, c-met, and mer inhibitors and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214344B1 (en) 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
CA2266448A1 (en) * 1996-09-24 1998-04-02 Eli Lilly And Company Coated particle formulation
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US20100016378A1 (en) * 2005-04-28 2010-01-21 Toshio Suzuki Method of preventing dihydropyridine compound from degradation
TR200504775A1 (tr) 2005-11-30 2007-10-22 Esen Beki̇r Kendinden metal takviyeli pvc pencere ve kapı profilleri
US8865722B2 (en) * 2006-01-05 2014-10-21 Teva Pharmaceutical Industries Ltd. Wet formulations of aripiprazole
MX2009004699A (es) * 2006-11-08 2009-05-15 Bristol Myers Squibb Co Compuestos de piridinona.
US20080260837A1 (en) * 2007-04-20 2008-10-23 Qpharma, L.L.C. Physically stable aqueous suspensions of active pharmaceuticals
US8263652B2 (en) * 2007-10-31 2012-09-11 Sk Biopharmaceuticals Co., Ltd. Stabilized pediatric suspension of carisbamate
EP2235001B1 (en) 2008-01-23 2014-12-24 Bristol-Myers Squibb Company Process for preparing pyridinone compounds

Also Published As

Publication number Publication date
SMT201500069B (it) 2015-05-05
EP2563763B1 (en) 2014-12-31
MY183769A (en) 2021-03-12
CN102971296A (zh) 2013-03-13
PL2563763T3 (pl) 2015-06-30
US8911785B2 (en) 2014-12-16
EP2563763A1 (en) 2013-03-06
WO2011137274A1 (en) 2011-11-03
US20130039989A1 (en) 2013-02-14
CN102971296B (zh) 2015-11-25
SG184891A1 (en) 2012-11-29
KR101897302B1 (ko) 2018-09-11
HRP20150105T1 (hr) 2015-03-13
ES2533075T3 (es) 2015-04-07
SI2563763T1 (sl) 2015-03-31
PT2563763E (pt) 2015-03-31
KR20130100237A (ko) 2013-09-10
JP2013525455A (ja) 2013-06-20
RS53790B1 (sr) 2015-06-30
PH12012502019A1 (en) 2017-08-18
US9233948B2 (en) 2016-01-12
DK2563763T3 (en) 2015-04-07
AU2011245269A1 (en) 2012-12-20
HK1179260A1 (en) 2013-09-27
US20150065719A1 (en) 2015-03-05

Similar Documents

Publication Publication Date Title
JP6756617B2 (ja) Ｎ−｛４−［（６，７−ジメトキシキノリン−４−イル）オキシ］フェニル｝−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドの結晶性固体形態、製造プロセス、及び使用方法
DK2409975T3 (en) Solid dispersions comprising an amorphous body composed of a heterocyclic anti-tumor compound
US20220194946A1 (en) Fgfr inhibitors and methods of making and using the same
EP2327697A1 (en) The salts of n-ý4-(1-cyanocyclopentyl)phenyl¨-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide
JP5820874B2 (ja) Ｎ−（４−（２−アミノ−３−クロロピリジン−４−イルオキシ）−３−フルオロフェニル）−４−エトキシ−１−（４−フルオロフェニル）−２−オキソ−１，２−ジヒドロピリジン−３−カルボキサミドを含有する医薬組成物
AU2011245269B2 (en) Pharmaceutical compositions comprising N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3 -carboxamide
CN112119062B (zh) 化合物晶型、其制备方法、药物组合物以及应用
HK1179260B (en) Pharmaceutical compositions comprising n-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-l-(4-fluorophenyl)-2-oxo- 1,2-dihydropyridine-3 -carboxamide
WO2022087763A1 (zh) 含有索拉非尼游离碱和5-氟尿嘧啶的共晶体、药物组合物及其用途
WO2025107298A1 (zh) 晶体、药物组合物及其制备方法和应用
TW202521542A (zh) 晶體、藥物組合物及其製備方法和應用
TW202440585A (zh) MDM2-p53抑制劑之晶型及醫藥組合物
TW202413343A (zh) ５－（２－（４－（４－氟－２－甲基－１ｈ－吲哚－５－基氧基）－６－甲氧基喹啉－７－基氧基）乙基）－５－氮雜螺［２．４］－庚－７－醇之結晶、磷酸鹽及其對映體之生物活性
WO2008157291A2 (en) CRYSTALLINE FORMS OF (3Aα, 4β, 5α, 7β, 7Aα)-4-(OCTAHYDRO-5-ETHYLSULFONAMIDO-4,7-DIMETHYL-1,3-DIOXO-4,7-EPOXY-2H-ISOINDOL-2-YL)-2-(TRIFLUOROMETHYL)BENZONITRILE AND METHOD OF PREPARATION
NZ723714B2 (en) Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140416

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140416

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150413

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150717

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150819

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150929

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151005

R150 Certificate of patent or registration of utility model

Ref document number: 5820874

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250